Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Belimumab, a monoclonal antibody that inhibits B-cell activating factor (BAFF), is one of the recently approved biologic adjunct in the management of lupus nephritis (LN) following its robust efficacy from the BLISS-LN trial. However, real world data remain limited among LN patients with AKI (particularly those with eGFR < 30 mls/min/1.73m2) or those with frequent relapses. We aim to report our single center experience on the outcomes of IV belimumab in these two challenging LN cohorts.
A retrospective study was conducted between January 2024 and October 2025, on LN patients initiated on IV Belimumab. Patients were classified into two cohorts:
Cohort 1 (n=3): Biopsy proven LN patients who developed AKI with eGFR < 30 mls/min/1.73m2.
Cohort 2 (n=6): Biopsy proven LN patients with frequent relapses, defined as ≥ 2 renal relapses within 36 months despite standard immunosuppression therapy.
Clinical and biochemical parameters such as serum creatinine, eGFR, albumin, urine protein-to-creatinine ratio (uPCR), and urine soluble CD163 were collected at baseline and at latest follow-up post belimumab.
All patients were female with mean age of 30 years. Median duration of follow-up is 9 months.
In the AKI cohort, there was improvement of eGFR from mean of 22 to 37 mls/min/1.73m2, with concomitant increase in serum albumin. Most patients also demonstrated 10-14% relative reduction proteinuria reduction following belimumab therapy. All patients demonstrated reduction in urine soluble CD163 that is more pronounced with higher IV belimumab doses. One patient developed herpes zoster infection after tenth dose of IV Belimumab.
Among the frequent relapsers, mean eGFR improved from 98.8 to 107.5 mls/min/1.73m2 , 3 out of 6 patients achieved reduction in proteinuria with resolution of hypoalbuminemia. All patients demonstrated reduction in urine soluble CD163. Most of the patients in this cohort received 4 doses of belimumab or less. None developed severe infection or infusion reaction.
Our experience with belimumab suggests its feasibility, preliminary efficacy and tolerability in treating LN patients with AKI and frequent relapses. Findings from this case series support the role of belimumab as an adjunct in difficult-to-treat lupus nephritis, warranting longer follow-up and multicentre validation.
